Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Launches Proseek® Multiplex

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
Company introduces scalable protein biomarker assays based on PEA platform.

Olink has launched Proseek® Multiplex - a new generation of multiplexed protein biomarker immunoassays based on its proprietary Proximity Extension Assay (PEA) platform.

Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously.

Now with the introduction of Proseek Multiplex, biomarker researchers can quantify 92 proteins in just one microliter sample without compromising data quality or performance.

"We are very proud at Olink to introduce a new and scalable era in immunoassays. Proseek has harnessed the tools that have fueled genomics for many years and put them to use in protein biomarker research. In a few years, we aim to offer the market’s most comprehensive portfolio of protein biomarker assays." says Simon Fredriksson, CEO of Olink Bioscience.

First in the range is Proseek Multiplex Oncology I 96x96, a ready-to-use kit sold by Olink capable of analyzing 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens.

Further Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes will be introduced through 2013.

Minimal sample consumption makes Proseek Multiplex especially suitable for retroactively mining precious biobanked serum samples for novel multivariate biomarker signatures.

It can also provide novel biomarker insights from sample types such as tissue lysates of needle biopsies and micro dialysis samples.

Even in these small samples Proseek Multiplex can provide accurate quantification below pico-gram per milliliter levels.

Proseek is based on the proprietary PEA technology developed at Olink.

PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons each ID-barcoding their respective antigens.

Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

"This is major breakthrough. Suddenly the extremely sensitive, reproducible and reliable qPCR workflow since long established as the gold standard for DNA, mRNA, and microRNA analyses has become available also for the measurement of proteins. During our early access period we have established robust SOPs for the entire workflow from sample preparation to data analysis, and it will be a great pleasure supporting our clients with this exceedingly powerful new technology to advance their research." says Professor Mikael Kubista, founder of TATAA Biocenter and renowned for his pioneering work in real time-PCR.

Proseek Multiplex is for research use only. Not for use in diagnostic procedures.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New European Consortium to Boost our Understanding of IBD
A multi-modal integrated biomarker study Consortium to increase diagnostic precision in detection of the diseases.
Thursday, May 23, 2013
Olink Bioscience Appoints Sigma-Aldrich as Distributor of Duolink
Olink Bioscience will continue to develop the protein biomarker market.
Friday, May 17, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!